Challenges in initiating antiretroviral therapy in 2010. - Wikidata - awgldk - TriplyDB

Challenges in initiating antiretroviral therapy in 2010.

Challenges in initiating antiretroviral therapy in 2010.

http://www.wikidata.org/entity/Q30227046

about

Challenges in initiating antiretroviral therapy in 2010.

http://www.wikidata.org/entity/Q30227046

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Challenges in initiating antiretroviral therapy in 2010.

@ast

Challenges in initiating antiretroviral therapy in 2010.

@en

type

label

Challenges in initiating antiretroviral therapy in 2010.

@ast

Challenges in initiating antiretroviral therapy in 2010.

@en

prefLabel

Challenges in initiating antiretroviral therapy in 2010.

@ast

Challenges in initiating antiretroviral therapy in 2010.

@en

P1433

Q30227046-4CDC448F-5BE8-462D-9514-2CFFF20330BF

P1476

Q30227046-50990663-D23A-46CA-A804-4A5FAB81B68B

P2093

Q30227046-0EAC2162-BF00-4806-8770-427EEC41141D

Q30227046-35155713-3909-4EDF-8A59-E2C16ED2B273

Q30227046-397F5052-B4C1-46FD-B5E1-E8A4E7144C2C

Q30227046-6002BD43-CF3E-48C6-9FAD-40196966F482

Q30227046-8E19FBF3-AE02-4DB2-8520-B854E9AC48A4

Q30227046-E1A0F4A4-9952-42A7-8EF8-FD86156E4DC9

Q30227046-E354C773-D0B4-41E1-8657-00A134DA694C

P2860

Q30227046-07172454-9F1A-4BF5-B4FC-87AAF526FC34

Q30227046-08408AD4-FBEE-414C-8518-7944888823F5

Q30227046-0AC1B08F-01BB-4D33-836F-1C23D4B4CE83

Q30227046-102B291D-FD32-4D40-9F41-738B022B9968

Q30227046-126E2FB3-5B1D-4720-B574-6667DE960C58

Q30227046-164DDCBC-5C89-4402-9613-EF7F59ACE410

Q30227046-17D4568D-9056-460E-AB42-EAA27E0A6AC7

Q30227046-1804E233-5789-4073-BA2B-F1C268BCE1B6

Q30227046-196E41D1-F9B2-4BAD-9066-5C5B4BB9C9D2

Q30227046-1A6A6882-8E43-46CD-80AE-66723B4B01B7

P304

Q30227046-D3961813-CB0C-49FD-932C-D2242C518AA1

P31

Q30227046-93D83C22-3A09-4CC1-958A-F35AA2D85AE6

P356

Q30227046-3072BCC5-AED3-4D78-B456-9DC9AE7D6B15

P407

Q30227046-9789509A-2426-42DF-9F5B-4790E0D21DE1

P478

Q30227046-3804489F-C3A5-4101-8995-8760B205AABF

P577

Q30227046-8476FADB-EA2E-4E11-B029-FF939D956D7D

P698

Q30227046-F2C635AC-454D-4AB3-83E3-E540C660C2AD

P921

Q30227046-86A89E6B-26FB-4C9B-AB5A-8E6513A75257

P932

Q30227046-8C4BADE9-9ED1-49E6-ACCC-056FB202FE0F

P356

P1433

Canadian Journal of Infectious Diseases & Medical Microbiology

P1476

Challenges in initiating antiretroviral therapy in 2010.

@en

P2093

Cécile L Tremblay

http://www.w3.org/2001/XMLSchema#string

David Fletcher

http://www.w3.org/2001/XMLSchema#string

Donald Kilby

http://www.w3.org/2001/XMLSchema#string

Jean-Guy Baril

http://www.w3.org/2001/XMLSchema#string

Mark W Tyndall

http://www.w3.org/2001/XMLSchema#string

Paul Macpherson

http://www.w3.org/2001/XMLSchema#string

Stephen D Shafran

http://www.w3.org/2001/XMLSchema#string

P2860

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Multi-Ethnic Study of Atherosclerosis: objectives and design

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART.

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Effect of early versus deferred antiretroviral therapy for HIV on survival.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

P304

1C-15C

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2010/165926

http://www.w3.org/2001/XMLSchema#string

P407

P478

21 Suppl C

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23365594

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3555474

http://www.w3.org/2001/XMLSchema#string